| 前收市價 | 102.38 |
| 開市 | 102.60 |
| 買盤 | 102.74 x 40000 |
| 賣出價 | 102.83 x 40000 |
| 今日波幅 | 102.57 - 103.12 |
| 52 週波幅 | 99.04 - 125.41 |
| 成交量 | |
| 平均成交量 | 670,169 |
| 市值 | 269.208B |
| Beta 值 (5 年，每月) | 0.31 |
| 市盈率 (最近 12 個月) | 21.86 |
| 每股盈利 (最近 12 個月) | 4.70 |
| 業績公佈日 | 2024年7月25日 |
| 遠期股息及收益率 | 3.28 (3.20%) |
| 除息日 | 2024年4月22日 |
| 1 年預測目標價 | 124.25 |
CNN BusinessNestlé and other companies are trying to stake their claims as weight loss drug experts. They’re not
As the use of popular weight loss and diabetes drugs like Wegovy and Ozempic skyrockets, consumer brands are scrambling to adapt. But health professionals are warning consumers not to take medical advice from the same companies trying to sell them food, supplements and other consumables.
Insider MonkeyNestlé (NSRGY): Do Analysts Recommend This Ice Cream Stock In 2024?
We recently compiled a list of the 11 Best Ice Cream Stocks to Invest In 2024. In this article, we are going to take a look at where Nestlé (OTC:NSRGY) stands against the other ice cream stocks. Regarded as the most favorite dessert globally, ice cream has its popularity game quite high in the U.S. […]
ReutersNestle, Coke take cautious approach to catering to Ozempic users
NEW YORK (Reuters) -Nestle's new food brand for people taking weight-loss drugs like Wegovy will note that the meals are high in protein, fiber and nutrients, but will not name the blockbuster medications, a company executive told Reuters. The world's largest food maker is keeping the names of the drugs off the packaging due to regulatory concerns, Tom Moe, Nestle USA's president of meals, said in a recent interview. Nestle will instead market its Vital Pursuit line of $5-and-under frozen meals on social media, he said.
